Announcing an Educational Webinar About Erleada


Jansen Pharmaceuticals has requested that we let our blog readers know about an upcoming educational webinar they are sponsoring on Tuesday, 9/18/18, 7 p.m. ET.  The webinar will be discussing their newly approved treatment, apalutamide (Erleada) which is approved by the FDA for men with castrate resistant, non-metastatic prostate cancer, sometimes referred to as M0 (M-zero) disease.  

The webinar will be hosted by Dr. David Crawford.

If you are interested in listening to the webinar you can dial in at: 833-877-2773 or you can use your computer by going to: http::// The conference code is 4198405